Chronic obstructive pulmonary disease

Related records

Broader conditions (9)

• Disease
• Disease by body system or component
• Human disease
• Lower respiratory tract disorder
• Lung disorder
• Obstructive lung disease
• Respiratory system disorder
• Tracheal disorder
• Upper respiratory tract disorder

Narrower conditions (14)

• Bronchiectasis
• Bronchiectasis with or without elevated sweat chloride 1
• Bronchiectasis with or without elevated sweat chloride 2
• Bronchiectasis with or without elevated sweat chloride 3
• Chronic bronchitis
• Compensatory emphysema
• Congenital lobar emphysema
• COPD, severe early onset
• Diffuse panbronchiolitis
• Emphysema, hereditary pulmonary
• Hyperlucent lung
• Idiopathic bronchiectasis
• Interstitial emphysema
• Pulmonary emphysema

Trials (3,928)

• : Vascular Function in Health and Disease
• 'Real Life' Monitoring of COPD no ICS Patients
• "Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"
• "The Effect of Inhaled Nitroglycerin for COPD Patients
• 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
• 12-week Efficacy of Indacaterol
• 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
• 14729-D9831C00002- 1 Month Biopsy Study
• 15-year Mortality After Hospitalization for Exacerbation of Chronic Obstructive Pulmonary Disease
• 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
• 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
• 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
• 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
• 3 Minutes Chair Rise Test (3CRT) in Patients With COPD
• 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
• 4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting
• 6-minute Stepper Test and Pulmonary Rehabilitation in Patients With Chronicle Obstructive Pulmonary Disease
• 6-minute Stepper Test and Pulmonary Rehabilitation in Patients With Severe to Very Severe Chronicle Obstructive Pulmonary Disease
• 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Approved drugs (22)

• Aclidinium bromide
• Albuterol
• Albuterol sulfate
• Arformoterol tartrate
• Azithromycin
• Budesonide
• Ensifentrine
• Fluticasone furoate
• Fluticasone propionate
• Formoterol fumarate
• Glycopyrronium bromide
• Glycopyrronium tosylate
• Indacaterol maleate
• Ipratropium bromide
• Olodaterol hydrochloride
• Prednisolone sodium phosphate
• Revefenacin
• Roflumilast
• Salmeterol xinafoate
• Tiotropium bromide

Drugs in development (230)

• .ALPHA.1-proteinase inhibitor human Phase 3
• Abediterol Phase 2
• Acetazolamide Phase 3
• Acetylcysteine Phase 3
• Aclidinium Phase 2
• Acumapimod Phase 2
• Aderamastat Phase 1
• Albumin human Phase 3
• Alvelestat Phase 2
• Amelubant Phase 2
• Amikacin Early phase 1
• Amikacin sulfate Phase 3
• Andecaliximab Phase 1
• Anti-psgl-1 antibody SELK2 Phase 2
• Apocynin Phase 1
• Arformoterol Phase 3
• Arofylline Phase 3
• ASM-024 Phase 2
• Aspirin Phase 3
• Astegolimab Phase 3

Other linked drugs (19)

• Almitrine
• Aprepitant
• Bamifylline
• Beclomethasone
• Bitolterol
• Carbocysteine
• Curcumin
• Ergocalciferol
• Fentanyl
• Fentanyl citrate
• Fluorometholone
• Levcromakalim
• Meprednisone
• Pimagedine
• Prasterone
• Pregabalin
• Stapokibart
• Telenzepine
• Zardaverine